Drug Profile
KW 2450
Alternative Names: KW-2450Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Kyowa Hakko Kirin
- Class Antineoplastics; Small molecules
- Mechanism of Action Insulin receptor antagonists; Insulin-like growth factor-I receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer; Solid tumours
Most Recent Events
- 17 Apr 2013 Discontinued - Phase-I for Solid tumours in USA (PO)
- 17 Apr 2013 Discontinued - Phase-I/II for Breast cancer in USA (PO)
- 24 Jan 2013 KW 2450 is still in Phase-I/II trials for Cancer in USA